Clozapine vs Paliperidone (Invega)

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Schizophrenia

Shared mechanism: Dopamine D2 and serotonin 5-HT2A receptors (antagonist) · full Schizophrenia pipeline

Clozapine

Marketed by HLS Therapeutics Inc.

Approved in Schizophreniasmall molecule
Weak signal

NCT00250575 · Phase 3 · completed

The study was open-label, single-arm, and had no placebo or active comparator; all 43 participants received clozapine. Its primary measures focused on hematological tests, blood-related adverse events, and monitoring-system compliance rather than a clinical symptom endpoint, and no results are posted.

Next expected readout: April 2027 · NCT04580134 (registry estimate)

Reported efficacy

Treatment efficacy rate (baseline,0.5 months,1 months, 2 months,4 months , 6 months , 8 months and 12 months); All-cause dropout rate (baseline,0.5 months,1 months, 2 months,4 months , 6 months , 8 months and 12 months): Primary 1, symptomatic response (40% or more PANSS total reduction) in phase 2 among 111 re-randomized nonresponders: clozapine 62.5% (20/32) vs amisulpride 44.7% (17/38) vs olanzapine 31.7% (13/41) (chi-square 6.9; P=.03), met. Primary 2, time to all-cause discontinuation: the paper reports no clear difference between treatment groups, missed. (mixed)

Result source: NCT03510325

Paliperidone (Invega)

Marketed by Johnson & Johnson

Approved in Schizophreniasmall molecule
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

Next expected readout: September 2027 · NCT04478838 (registry estimate)

Reported efficacy

Number of Participants With Relapse (Up to Day 730); Number of Participants With Treatment-emergent Adverse Events (TEAEs) (Up to Day 730): Number of Participants With Relapse (Up to Day 730): Total Paliperidone Palmitate 6-month (PP6M) 700 or 1000 mg eq. 7/178 (not_applicable)

Result source: NCT04072575

Results for Schizophrenia

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

These assets measured different things. Their trials share no endpoint in common, so no efficacy row can be built. That is a property of the programmes rather than a gap in the record: each asset's own reported endpoints are listed below.

Key endpointClozapinePaliperidone (Invega)
PANSS total, change—Not posted · NCT00649844-9.8 vs -7.9−1.9 vs placebowk 6 · n 54NCT00518323
8 other results
  • -17.3 vs -7.9 wk 6 · n 48 · Phase 3 · primary NCT00518323
  • -13.8 vs -7.9 wk 6 · n 47 · Phase 3 · primary NCT00518323
  • -9.1 vs 3.8 wk 6 · n 134 · Phase 3 · primary NCT00396565
  • -19.3 vs -19.8 wk 8 · n 112 · Phase 3 · primary NCT01009047
  • -25.6 vs -26.8 wk 26 · n 112 · Phase 3 · secondary NCT01009047
  • -13.5 vs -16.6 wk 24 · n 234 · Phase 3 · secondary NCT00645099
  • -15 vs -11.7 6 mg · wk 6 · n 70 · Phase 4 · primary NCT00524043
  • -8.9 vs -11.7 1.5 mg · wk 6 · n 66 · Phase 4 · primary NCT00524043
CGI-S, change—Not posted · NCT006498440 vs 0±0 vs placebowk 6 · n 54NCT00518323
7 other results
  • -1 vs 0 wk 6 · n 48 · Phase 3 · secondary NCT00518323
  • -1 vs 0 wk 6 · n 47 · Phase 3 · secondary NCT00518323
  • -0.4 vs 0.2 wk 6 · n 134 · Phase 3 · secondary NCT00396565
  • -1 vs -1 wk 26 · n 112 · Phase 3 · secondary NCT01009047
  • -1 vs -1 wk 8 · n 112 · Phase 3 · secondary NCT01009047
  • -0.5 vs -1 6 mg · wk 6 · n 70 · Phase 4 · secondary NCT00524043
  • 0 vs -1 1.5 mg · wk 6 · n 66 · Phase 4 · secondary NCT00524043
PANSS response—Not posted · NCT0064984476.8% vs 81.6%vs Aripiprazolewk 26 · n 112NCT01009047
1 other result
  • 67.9% vs 76.3% wk 8 · n 112 · Phase 3 · secondary NCT01009047
PSP, change—Not posted · NCT0064984417.1 vs 17.1vs Aripiprazolewk 26 · n 112NCT01009047
3 other results
  • 12.2 vs 12.2 wk 8 · n 112 · Phase 3 · secondary NCT01009047
  • 5.7 vs 1.6 6 mg · wk 6 · n 70 · Phase 4 · secondary NCT00524043
  • 2.9 vs 1.6 1.5 mg · wk 6 · n 66 · Phase 4 · secondary NCT00524043
Relapse (% of patients)—Not posted · NCT00649844—Not posted · NCT03485417

PANSS total, change

Clozapine
—Not posted · NCT00649844
Paliperidone (Invega)
-9.8 vs -7.9−1.9 vs placebowk 6 · n 54NCT00518323
8 other results
  • -17.3 vs -7.9 wk 6 · n 48 · Phase 3 · primary NCT00518323
  • -13.8 vs -7.9 wk 6 · n 47 · Phase 3 · primary NCT00518323
  • -9.1 vs 3.8 wk 6 · n 134 · Phase 3 · primary NCT00396565
  • -19.3 vs -19.8 wk 8 · n 112 · Phase 3 · primary NCT01009047
  • -25.6 vs -26.8 wk 26 · n 112 · Phase 3 · secondary NCT01009047
  • -13.5 vs -16.6 wk 24 · n 234 · Phase 3 · secondary NCT00645099
  • -15 vs -11.7 6 mg · wk 6 · n 70 · Phase 4 · primary NCT00524043
  • -8.9 vs -11.7 1.5 mg · wk 6 · n 66 · Phase 4 · primary NCT00524043

CGI-S, change

Clozapine
—Not posted · NCT00649844
Paliperidone (Invega)
0 vs 0±0 vs placebowk 6 · n 54NCT00518323
7 other results
  • -1 vs 0 wk 6 · n 48 · Phase 3 · secondary NCT00518323
  • -1 vs 0 wk 6 · n 47 · Phase 3 · secondary NCT00518323
  • -0.4 vs 0.2 wk 6 · n 134 · Phase 3 · secondary NCT00396565
  • -1 vs -1 wk 26 · n 112 · Phase 3 · secondary NCT01009047
  • -1 vs -1 wk 8 · n 112 · Phase 3 · secondary NCT01009047
  • -0.5 vs -1 6 mg · wk 6 · n 70 · Phase 4 · secondary NCT00524043
  • 0 vs -1 1.5 mg · wk 6 · n 66 · Phase 4 · secondary NCT00524043

PANSS response

Clozapine
—Not posted · NCT00649844
Paliperidone (Invega)
76.8% vs 81.6%vs Aripiprazolewk 26 · n 112NCT01009047
1 other result
  • 67.9% vs 76.3% wk 8 · n 112 · Phase 3 · secondary NCT01009047

PSP, change

Clozapine
—Not posted · NCT00649844
Paliperidone (Invega)
17.1 vs 17.1vs Aripiprazolewk 26 · n 112NCT01009047
3 other results
  • 12.2 vs 12.2 wk 8 · n 112 · Phase 3 · secondary NCT01009047
  • 5.7 vs 1.6 6 mg · wk 6 · n 70 · Phase 4 · secondary NCT00524043
  • 2.9 vs 1.6 1.5 mg · wk 6 · n 66 · Phase 4 · secondary NCT00524043

Relapse (% of patients)

Clozapine
—Not posted · NCT00649844
Paliperidone (Invega)
—Not posted · NCT03485417
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Clozapine: 3 of 4 rows · Paliperidone (Invega): 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricClozapinePaliperidone (Invega)
Dropout rate
41.7%a
NCT01639872 · Phase 4 · registry result, not featured evidence
show 2 more results
0%
NCT00498550 · Phase 4 · registry result, not featured evidence
17.2%
NCT02404155 · Phase na · registry result, not featured evidence
41.2%a
NCT00784238 · Phase 4 · registry result, not featured evidence
show 35 more results
48.4%
NCT00761579 · Phase 4 · registry result, not featured evidence
36.4%
NCT00761605 · Phase 4 · registry result, not featured evidence
20%
NCT01387542 · Phase 4 · registry result, not featured evidence
11.3%
NCT01362439 · Phase 4 · registry result, not featured evidence
—Paliperidone ER - Extension Phase
NCT01010776 · Phase 4 · registry result, not featured evidence
—Paliperidone ER - Main Phase
NCT01010776 · Phase 4 · registry result, not featured evidence
32.6%
NCT01724359 · Phase 4 · registry result, not featured evidence
27.1%
NCT01577186 · Phase 4 · registry result, not featured evidence
40.5%
NCT00757705 · Phase 4 · registry result, not featured evidence
27.8%
NCT01577160 · Phase 4 · registry result, not featured evidence
—Paliperidone ER Phase
NCT00535145 · Phase 4 · registry result, not featured evidence
25.4%Study Treatment
NCT00535145 · Phase 4 · registry result, not featured evidence
—TAU - Pali ER
NCT00535145 · Phase 4 · registry result, not featured evidence
40%6 mg
NCT00524043 · Phase 4 · registry result, not featured evidence
47%1.5 mg
NCT00524043 · Phase 4 · registry result, not featured evidence
0%PALI ER Delayed Initiation
NCT00535132 · Phase 4 · registry result, not featured evidence
0%PALI ER Immediate Initiation
NCT00535132 · Phase 4 · registry result, not featured evidence
—Paliperidone DB/Paliperidone Open-
NCT01662310 · Phase 3 · registry result, not featured evidence
—Paliperidone: Double Blind (DB) Ph
NCT01662310 · Phase 3 · registry result, not featured evidence
36.4%Paliperidone (Double-blind)/Palipe
NCT00488319 · Phase 3 · registry result, not featured evidence
50.2%Paliperidone (No Double-blind)/Pal
NCT00488319 · Phase 3 · registry result, not featured evidence
38.5%Placebo/Paliperidone
NCT00488319 · Phase 3 · registry result, not featured evidence
24.8%
NCT01009047 · Phase 3 · registry result, not featured evidence
19.1%
NCT01541371 · Phase 3 · registry result, not featured evidence
50%
NCT00473434 · Phase 3 · registry result, not featured evidence
20.4%
NCT00566631 · Phase 3 · registry result, not featured evidence
—
NCT00645099 · Phase 3 · registry result, not featured evidence
28.3%Paliperidone ER: Lack of Efficacy
NCT01662648 · Phase 3 · registry result, not featured evidence
29.8%Paliperidone ER: Lack of Tolerabil
NCT01662648 · Phase 3 · registry result, not featured evidence
22.9%Pali ER High
NCT00518323 · Phase 3 · registry result, not featured evidence
35.2%Pali ER Low
NCT00518323 · Phase 3 · registry result, not featured evidence
16.7%Pali ER Medium
NCT00518323 · Phase 3 · registry result, not featured evidence
15.4%
NCT01606228 · Phase 3 · registry result, not featured evidence
45.4%
NCT01561898 · Phase 3 · registry result, not featured evidence
35.3%
NCT00396565 · Phase 3 · registry result, not featured evidence
Discontinued due to AEs
—a
NCT01639872 · Phase 4 · registry result, not featured evidence
show 2 more results
—
NCT00498550 · Phase 4 · registry result, not featured evidence
—
NCT02404155 · Phase na · registry result, not featured evidence
4.8%a
NCT00784238 · Phase 4 · registry result, not featured evidence
show 35 more results
5.3%
NCT00761579 · Phase 4 · registry result, not featured evidence
6.7%
NCT00761605 · Phase 4 · registry result, not featured evidence
7.5%
NCT01387542 · Phase 4 · registry result, not featured evidence
0.8%
NCT01362439 · Phase 4 · registry result, not featured evidence
—Paliperidone ER - Extension Phase
NCT01010776 · Phase 4 · registry result, not featured evidence
—Paliperidone ER - Main Phase
NCT01010776 · Phase 4 · registry result, not featured evidence
10.5%
NCT01724359 · Phase 4 · registry result, not featured evidence
4.8%
NCT01577186 · Phase 4 · registry result, not featured evidence
6.4%
NCT00757705 · Phase 4 · registry result, not featured evidence
2.5%
NCT01577160 · Phase 4 · registry result, not featured evidence
—Paliperidone ER Phase
NCT00535145 · Phase 4 · registry result, not featured evidence
2.6%Study Treatment
NCT00535145 · Phase 4 · registry result, not featured evidence
—TAU - Pali ER
NCT00535145 · Phase 4 · registry result, not featured evidence
2.9%6 mg
NCT00524043 · Phase 4 · registry result, not featured evidence
10.6%1.5 mg
NCT00524043 · Phase 4 · registry result, not featured evidence
—PALI ER Delayed Initiation
NCT00535132 · Phase 4 · registry result, not featured evidence
—PALI ER Immediate Initiation
NCT00535132 · Phase 4 · registry result, not featured evidence
—Paliperidone DB/Paliperidone Open-
NCT01662310 · Phase 3 · registry result, not featured evidence
—Paliperidone: Double Blind (DB) Ph
NCT01662310 · Phase 3 · registry result, not featured evidence
1.7%Paliperidone (Double-blind)/Palipe
NCT00488319 · Phase 3 · registry result, not featured evidence
9.5%Paliperidone (No Double-blind)/Pal
NCT00488319 · Phase 3 · registry result, not featured evidence
2.6%Placebo/Paliperidone
NCT00488319 · Phase 3 · registry result, not featured evidence
4.4%
NCT01009047 · Phase 3 · registry result, not featured evidence
3.7%
NCT01541371 · Phase 3 · registry result, not featured evidence
4.7%
NCT00473434 · Phase 3 · registry result, not featured evidence
3.1%
NCT00566631 · Phase 3 · registry result, not featured evidence
—
NCT00645099 · Phase 3 · registry result, not featured evidence
8.3%Paliperidone ER: Lack of Efficacy
NCT01662648 · Phase 3 · registry result, not featured evidence
6.2%Paliperidone ER: Lack of Tolerabil
NCT01662648 · Phase 3 · registry result, not featured evidence
2.1%Pali ER High
NCT00518323 · Phase 3 · registry result, not featured evidence
1.9%Pali ER Low
NCT00518323 · Phase 3 · registry result, not featured evidence
2.1%Pali ER Medium
NCT00518323 · Phase 3 · registry result, not featured evidence
0.5%
NCT01606228 · Phase 3 · registry result, not featured evidence
14.4%
NCT01561898 · Phase 3 · registry result, not featured evidence
3.7%
NCT00396565 · Phase 3 · registry result, not featured evidence
Serious AEs
13%a
NCT01639872 · Phase 4 · registry result, not featured evidence
show 2 more results
26.7%
NCT00498550 · Phase 4 · registry result, not featured evidence
6.9%
NCT02404155 · Phase na · registry result, not featured evidence
7.3%a
NCT00784238 · Phase 4 · registry result, not featured evidence
show 35 more results
12.1%
NCT00761579 · Phase 4 · registry result, not featured evidence
9.8%
NCT00761605 · Phase 4 · registry result, not featured evidence
2.5%
NCT01387542 · Phase 4 · registry result, not featured evidence
0.8%
NCT01362439 · Phase 4 · registry result, not featured evidence
1.9%Paliperidone ER - Extension Phase
NCT01010776 · Phase 4 · registry result, not featured evidence
6.5%Paliperidone ER - Main Phase
NCT01010776 · Phase 4 · registry result, not featured evidence
7.4%
NCT01724359 · Phase 4 · registry result, not featured evidence
7.7%
NCT01577186 · Phase 4 · registry result, not featured evidence
3.7%
NCT00757705 · Phase 4 · registry result, not featured evidence
0%
NCT01577160 · Phase 4 · registry result, not featured evidence
2.4%Paliperidone ER Phase
NCT00535145 · Phase 4 · registry result, not featured evidence
—Study Treatment
NCT00535145 · Phase 4 · registry result, not featured evidence
0%TAU - Pali ER
NCT00535145 · Phase 4 · registry result, not featured evidence
7.1%6 mg
NCT00524043 · Phase 4 · registry result, not featured evidence
10.6%1.5 mg
NCT00524043 · Phase 4 · registry result, not featured evidence
4%PALI ER Delayed Initiation
NCT00535132 · Phase 4 · registry result, not featured evidence
3.1%PALI ER Immediate Initiation
NCT00535132 · Phase 4 · registry result, not featured evidence
4.3%Paliperidone DB/Paliperidone Open-
NCT01662310 · Phase 3 · registry result, not featured evidence
3.1%Paliperidone: Double Blind (DB) Ph
NCT01662310 · Phase 3 · registry result, not featured evidence
3.4%Paliperidone (Double-blind)/Palipe
NCT00488319 · Phase 3 · registry result, not featured evidence
18.9%Paliperidone (No Double-blind)/Pal
NCT00488319 · Phase 3 · registry result, not featured evidence
23.1%Placebo/Paliperidone
NCT00488319 · Phase 3 · registry result, not featured evidence
6.2%
NCT01009047 · Phase 3 · registry result, not featured evidence
0.2%
NCT01541371 · Phase 3 · registry result, not featured evidence
42.2%
NCT00473434 · Phase 3 · registry result, not featured evidence
7.8%
NCT00566631 · Phase 3 · registry result, not featured evidence
8.8%
NCT00645099 · Phase 3 · registry result, not featured evidence
6.8%Paliperidone ER: Lack of Efficacy
NCT01662648 · Phase 3 · registry result, not featured evidence
4.9%Paliperidone ER: Lack of Tolerabil
NCT01662648 · Phase 3 · registry result, not featured evidence
2.1%Pali ER High
NCT00518323 · Phase 3 · registry result, not featured evidence
3.7%Pali ER Low
NCT00518323 · Phase 3 · registry result, not featured evidence
2.1%Pali ER Medium
NCT00518323 · Phase 3 · registry result, not featured evidence
2.1%
NCT01606228 · Phase 3 · registry result, not featured evidence
—
NCT01561898 · Phase 3 · registry result, not featured evidence
3%
NCT00396565 · Phase 3 · registry result, not featured evidence
Most frequent reported AEs
a
other-sialorrhea 43.5%
weight gain 30.4%
sedation 21.7%
NCT01639872 · Phase 4 · registry result, not featured evidence
show 2 more results
gastrointestinal disorder - other: hypersalivation 66.7%
somnolence 60%
weight gain 40%
NCT00498550 · Phase 4 · registry result, not featured evidence
salivation 68.2%
sedation 52.9%
malaise 52.6%
NCT02404155 · Phase na · registry result, not featured evidence
a
akathisia 8.3%
extrapyramidal disorder 4.8%
insomnia 4.8%
NCT00784238 · Phase 4 · registry result, not featured evidence
show 33 more results
akathisia 18.4%
weight increased 15.3%
muscle rigidity 7.4%
NCT00761579 · Phase 4 · registry result, not featured evidence
insomnia 12.4%
akathisia 11.4%
weight increased 9.3%
NCT00761605 · Phase 4 · registry result, not featured evidence
drowsiness 15%
headache 15%
insomnia 12.5%
NCT01387542 · Phase 4 · registry result, not featured evidence
insomnia 3%
weight increase 3%
extrapyramidal symptoms 2.3%
NCT01362439 · Phase 4 · registry result, not featured evidence
weight increased 12.6%
insomnia 8.8%
depression 4.4%
NCT01010776 · Phase 4 · registry result, not featured evidence
insomnia 14.9%
anxiety 10.7%
weight increased 10.7%
NCT01010776 · Phase 4 · registry result, not featured evidence
insomnia 25.3%
akathisia 23.2%
parkinsonism 15.8%
NCT01724359 · Phase 4 · registry result, not featured evidence
extrapyramidal disorder 11.7%
upper respiratory tract infection 6.7%
tremor 4.8%
NCT01577186 · Phase 4 · registry result, not featured evidence
insomnia 20.7%
extrapyramidal disorder 13.7%
anxiety 11.7%
NCT00757705 · Phase 4 · registry result, not featured evidence
insomnia 15.9%
constipation 11.3%
extrapyramidal disorder 9.6%
NCT01577160 · Phase 4 · registry result, not featured evidence
tremor 8.3%
headache 7.1%
nausea 6%
NCT00535145 · Phase 4 · registry result, not featured evidence
weight increased 6%
headache 3.6%
akathisia 2.4%
NCT00535145 · Phase 4 · registry result, not featured evidence
6 mg
headache 11.4% (placebo 15.6%)
insomnia 10% (placebo 9.4%)
tremor 10% (placebo 3.1%)
NCT00524043 · Phase 4 · registry result, not featured evidence
1.5 mg
insomnia 13.6% (placebo 9.4%)
dizziness 7.6% (placebo 1.6%)
headache 7.6% (placebo 15.6%)
NCT00524043 · Phase 4 · registry result, not featured evidence
constipation 9.1%
insomnia 9.1%
somnolence 8.1%
NCT00535132 · Phase 4 · registry result, not featured evidence
insomnia 9.2%
headache 8.2%
constipation 6.1%
NCT00535132 · Phase 4 · registry result, not featured evidence
constipation 4.3% (placebo 3.4%)
akathisia 2.1% (placebo 5.1%)
headache 2.1% (placebo 1.7%)
NCT01662310 · Phase 3 · registry result, not featured evidence
akathisia 4.7% (placebo 5.1%)
nausea 3.1% (placebo 0%)
tremor 3.1% (placebo 0%)
NCT01662310 · Phase 3 · registry result, not featured evidence
nasopharyngitis 15.3%
somnolence 15.3%
tremor 10.2%
NCT00488319 · Phase 3 · registry result, not featured evidence
weight increased 24.3%
headache 18.9%
somnolence 18.5%
NCT00488319 · Phase 3 · registry result, not featured evidence
somnolence 25.6%
insomnia 17.9%
anxiety 10.3%
NCT00488319 · Phase 3 · registry result, not featured evidence
akathisia 11.5%
headache 10.6%
somnolence 10.6%
NCT01009047 · Phase 3 · registry result, not featured evidence
akathisia 18.4%
tremor 12.9%
dystonia 8.7%
NCT01541371 · Phase 3 · registry result, not featured evidence
insomnia 15.6%
headache 10.9%
akathisia 9.4%
NCT00473434 · Phase 3 · registry result, not featured evidence
insomnia 23.1%
tachycardia 8.5%
headache 7.5%
NCT00566631 · Phase 3 · registry result, not featured evidence
insomnia 9.6%
weight increased 9.6%
headache 4.6%
NCT00645099 · Phase 3 · registry result, not featured evidence
insomnia 9.8%
extrapyramidal disorder 6.6%
headache 4.5%
NCT01662648 · Phase 3 · registry result, not featured evidence
insomnia 11.6%
headache 4.1%
nausea 3.9%
NCT01662648 · Phase 3 · registry result, not featured evidence
somnolence 20.8% (placebo 2%)
akathisia 16.7% (placebo 0%)
insomnia 12.5% (placebo 21.6%)
NCT00518323 · Phase 3 · registry result, not featured evidence
headache 9.3% (placebo 3.9%)
insomnia 9.3% (placebo 21.6%)
schizophrenia 9.3% (placebo 7.8%)
NCT00518323 · Phase 3 · registry result, not featured evidence
somnolence 14.6% (placebo 2%)
akathisia 8.3% (placebo 0%)
tremor 8.3% (placebo 0%)
NCT00518323 · Phase 3 · registry result, not featured evidence
insomnia 13.3%
anemia 4.8%
acute psychotic symptoms 1.6%
NCT01606228 · Phase 3 · registry result, not featured evidence
schizophrenia 16.4% (placebo 42.8%)
insomnia 11.2% (placebo 10.1%)
nasopharyngitis 10.4% (placebo 8%)
NCT00396565 · Phase 3 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Clozapine

Cannabis Use Intensity Joints Per 2.36 vs 2.35 Risperidone months @ 12wk
absolute value · months
NCT01639872 · Phase 4 · registry result, not featured evidence · converted to months from 10.21 weeks as posted
Cannabis Use Frequency Days Per 0.14 vs 0.15 Risperidone months @ 12wk
absolute value · months
NCT01639872 · Phase 4 · registry result, not featured evidence · converted to months from 4.26 days as posted
Cannabis Use Joints Per 0.02 per week
absolute value · per week
No placebo or comparator arm
NCT00498550 · Phase 4 · registry result, not featured evidence

Paliperidone (Invega)

SWN-K Total 77.89 score @ 24wk
absolute value · score
No placebo or comparator arm
NCT00784238 · Phase 4 · registry result, not featured evidence
SWN-K Total -1.59 score @ 24wk
absolute change · score
No placebo or comparator arm
NCT00784238 · Phase 4 · registry result, not featured evidence
show 2 more results
-2.66 score @ 24wk
NCT00784238 · Phase 4 · registry result, not featured evidence
-0.93 score @ 24wk
NCT00784238 · Phase 4 · registry result, not featured evidence
SWN-K Mental Functioning -0.14 score @ 24wk
absolute change · score
No placebo or comparator arm
NCT00784238 · Phase 4 · registry result, not featured evidence
show 2 more results
-0.51 score @ 24wk
NCT00784238 · Phase 4 · registry result, not featured evidence
-0.24 score @ 24wk
NCT00784238 · Phase 4 · registry result, not featured evidence
SWN-K Self Control -0.72 score @ 24wk
absolute change · score
No placebo or comparator arm
NCT00784238 · Phase 4 · registry result, not featured evidence
show 2 more results
-0.62 score @ 24wk
NCT00784238 · Phase 4 · registry result, not featured evidence
-0.29 score @ 24wk
NCT00784238 · Phase 4 · registry result, not featured evidence
SWN-K Emotional Regulation -0.07 score @ 24wk
absolute change · score
No placebo or comparator arm
NCT00784238 · Phase 4 · registry result, not featured evidence
show 2 more results
0.11 score @ 24wk
NCT00784238 · Phase 4 · registry result, not featured evidence
0.45 score @ 24wk
NCT00784238 · Phase 4 · registry result, not featured evidence
SWN-K Physical Functioning -0.11 score @ 24wk
absolute change · score
No placebo or comparator arm
NCT00784238 · Phase 4 · registry result, not featured evidence
show 2 more results
-0.68 score @ 24wk
NCT00784238 · Phase 4 · registry result, not featured evidence
0.47 score @ 24wk
NCT00784238 · Phase 4 · registry result, not featured evidence
SWN-K Social Integration -0.55 score @ 24wk
absolute change · score
No placebo or comparator arm
NCT00784238 · Phase 4 · registry result, not featured evidence
show 2 more results
-0.96 score @ 24wk
NCT00784238 · Phase 4 · registry result, not featured evidence
-1.31 score @ 24wk
NCT00784238 · Phase 4 · registry result, not featured evidence
DAI-10 Total 3.58 score @ 24wk
absolute value · score
No placebo or comparator arm
NCT00784238 · Phase 4 · registry result, not featured evidence
DAI-10 Total -0.46 score @ 24wk
absolute change · score
No placebo or comparator arm
NCT00784238 · Phase 4 · registry result, not featured evidence
show 3 more results
-0.21 score @ 24wk
NCT00784238 · Phase 4 · registry result, not featured evidence
-1 score @ 24wk
NCT00784238 · Phase 4 · registry result, not featured evidence
1 score @ 12wk
NCT01577160 · Phase 4 · registry result, not featured evidence
SCL90-R 2.42 score @ 24wk
absolute change · score
No placebo or comparator arm
NCT00784238 · Phase 4 · registry result, not featured evidence
show 2 more results
9.4 score @ 24wk
NCT00784238 · Phase 4 · registry result, not featured evidence
1.16 score @ 24wk
NCT00784238 · Phase 4 · registry result, not featured evidence
Krawiecka 0.94 score @ 24wk
absolute change · score
No placebo or comparator arm
NCT00784238 · Phase 4 · registry result, not featured evidence
show 2 more results
1.09 score @ 24wk
NCT00784238 · Phase 4 · registry result, not featured evidence
1.09 score @ 24wk
NCT00784238 · Phase 4 · registry result, not featured evidence
PSP -6.5 score @ 24wk
absolute change · score
No placebo or comparator arm
NCT00784238 · Phase 4 · registry result, not featured evidence
show 25 more results
-7.23 score @ 24wk
NCT00784238 · Phase 4 · registry result, not featured evidence
-6.28 score @ 24wk
NCT00784238 · Phase 4 · registry result, not featured evidence
-4.289 score @ 2wk
NCT01387542 · Phase 4 · registry result, not featured evidence
-7.053 score @ 6wk
NCT01387542 · Phase 4 · registry result, not featured evidence
-9.868 score @ 10wk
NCT01387542 · Phase 4 · registry result, not featured evidence
59.44 score @ 4wk
NCT00761189 · Phase 4 · registry result, not featured evidence
62.76 score @ 12wk
NCT00761189 · Phase 4 · registry result, not featured evidence
60.27 score @ 4wk
NCT00761189 · Phase 4 · registry result, not featured evidence
64.73 score @ 12wk
NCT00761189 · Phase 4 · registry result, not featured evidence
9.05 score @ 13wk
NCT01362439 · Phase 4 · registry result, not featured evidence
5.7 score @ 4wk
NCT01010776 · Phase 4 · registry result, not featured evidence
8.3 score @ 8wk
NCT01010776 · Phase 4 · registry result, not featured evidence
9.9 score @ 13wk
NCT01010776 · Phase 4 · registry result, not featured evidence
10.4 score @ 26wk
NCT01010776 · Phase 4 · registry result, not featured evidence
68.24 score @ 26wk
NCT01724359 · Phase 4 · registry result, not featured evidence
9.05 score @ 12wk
NCT01577186 · Phase 4 · registry result, not featured evidence
3.4 score @ 24wk
NCT00757705 · Phase 4 · registry result, not featured evidence
14.3 score @ 12wk
NCT01577160 · Phase 4 · registry result, not featured evidence
2.8 score @ 8.86wk
NCT00535145 · Phase 4 · registry result, not featured evidence
6.3 score @ 1wk
NCT00566631 · Phase 3 · registry result, not featured evidence
9.9 score @ 2wk
NCT00566631 · Phase 3 · registry result, not featured evidence
13.8 score @ 4wk
NCT00566631 · Phase 3 · registry result, not featured evidence
16.1 score @ 6wk
NCT00566631 · Phase 3 · registry result, not featured evidence
13.76 score @ 26wk
NCT01662648 · Phase 3 · registry result, not featured evidence
11.14 score @ 26wk
NCT01662648 · Phase 3 · registry result, not featured evidence

+ 69 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Clozapine's landscape · Paliperidone (Invega)'s landscape